YMFOcare: The impact of providing feedback on patients* symptoms and health-related quality of life and offering a self-management website on the self-management of patients with lymphoma. A randomized controlled population-based registry trial.
Completed
- Conditions
- haematological malignancyHodgkin and non-Hodgkin lymphoma10025323
- Registration Number
- NL-OMON42473
- Lead Sponsor
- Integraal Kankercentrum Nederland (IKNL)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
All patients (men and women) that are newly diagnosed with Hodgkin or non-Hodgkin lymphoma in one of the participating hospitals and were 18 years or older at time of diagnosis.
Exclusion Criteria
Unable to complete a Dutch questionnaire.
Patients with severe psychopathology or dementia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>self-management and psychological distress.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Anxiety and depression, health care utilization, psychological empowerment,<br /><br>health-related quality of life (HRQoL) generic and specific, symptoms, illness<br /><br>perceptions, personal control, coping, satisfaction with information provision,<br /><br>remoralization, and fatigue.</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted by digital health interventions in lymphoma self-management?
How does symptom feedback via LYMFOcare compare to standard care in improving quality of life for Hodgkin and non-Hodgkin lymphoma patients?
Which biomarkers correlate with successful self-management outcomes in population-based lymphoma trials like NL-OMON42473?
What adverse events are associated with digital self-management platforms in haematological malignancy patients?
How do combination approaches of digital tools and existing lymphoma therapies enhance patient outcomes in IKNL-sponsored trials?